
Therapeutic options for breast cancer have recently been enriched by new antibody-drug conjugates (ADC), which are now being utilized across all known molecular subtypes. ADCs represent a groundbreaking class of therapies that combine a cytotoxic agent with a monoclonal antibody via a combination molecule (linker). The primary objective is to selectively deliver chemotherapy to cells expressing the target antigen, thereby enhancing the therapeutic index. Trastuzumab-emtansine marked the pioneering use of this approach for HER2-overexpressed breast cancer. More recently, trastuzumab-deruxtecan and sacituzumab-govitecan have demonstrated efficacy in progression-free survival and overall survival in HER2-overexpressed and HER2-low breast cancer for the former, and HER2-non-overexpressed (including HER-low) for the latter. Numerous other ADCs are currently under development in breast cancer. While ADCs were initially designed to widen the therapeutic index and mitigate toxicities, managing ADC-related adverse events in the clinical setting remains a challenge. This review article aims to provide an overview of the toxicity profiles of these drugs already in current clinical practice or under development, drawing from results observed in various studies.
Immunoconjugates, Antineoplastic Agents, Immunological, Humans, Breast Neoplasms, Female, Maytansine, Camptothecin, Trastuzumab, Antibodies, Monoclonal, Humanized, Ado-Trastuzumab Emtansine, Erb-b2 Receptor Tyrosine Kinases
Immunoconjugates, Antineoplastic Agents, Immunological, Humans, Breast Neoplasms, Female, Maytansine, Camptothecin, Trastuzumab, Antibodies, Monoclonal, Humanized, Ado-Trastuzumab Emtansine, Erb-b2 Receptor Tyrosine Kinases
| citations The total number of citations received by all articles of the researcher of interest. | 1 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
